Short-Course Immunotherapy Shows Five-Year Recurrence-Free Survival in dMMR Colon Cancer

Long-term results from the NICHE-2 study, published in The Lancet and presented at ESMO 2026, indicate that a short course of immunotherapy given before surgery prevented disease recurrence for five years in all patients with non-metastatic mismatch repair-deficient (dMMR) colon cancer. This finding suggests a foundational shift in the treatment approach for this specific type of colon cancer.